Novo Nordisk : After diabetes, semaglutide gets off to a good start in obesity
>Positive initial data in phase III trial - Novo Nordisk yesterday evening, after the close, announced initial data from the phase III trial for its weekly GLP-1 semaglutide in obesity. STEP 4 successfully demonstrated the benefit of maintaining patients on semaglutide beyond an initial treatment period of 20 weeks. The 803 patients reaching the target dose of 2.4 mg of semaglutide after 20 weeks saw a weight reduction of around 10% (mean body weight down from 107.2 k...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.